USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIONEX PHARMACEUTICALS, LLC
Address:
7 LAVENDER WAY
EAST BRUNSWICK, NJ
Phone:
N/A
URL:
N/A
EIN:
126034306
DUNS:
807004242
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $283,479.00 2
SBIR Phase II $742,229.00 1

Award List:

Oral Transmucosal Drug Delivery System for Nicotine

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$117,968.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): RESEARCH PROPOSED: Research is proposed to investigate the feasibility of design and fabrication of an oral transmucosal drug delivery system for systemic delivery of nicotine. The drug delivery system is intended to at tain a dual drug-release profile so that… More

Oral transmucosal drug delivery system for naltrexone for alcohol dependence trea

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$165,511.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This proposed SBIR Phase I project will demonstrate the feasibility of developing a novel oral transmucosal drug delivery method and dosage form for alcohol dependence treatment. The proposed system is a small, thin, an d flexible film, containing the treatment… More

Oral transmucosal drug delivery system for naltrexone

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$742,229.00
Agency:
HHS
Principal Investigator:
Hock S. Tan – 732-967-0380
Abstract:
DESCRIPTION (provided by applicant): The proposed SBIR Phase II project aims at developing a new drug product, the naltrexone orally dissolving film (ODF), for treatment of alcohol dependence. The naltrexone ODF is a small, thin, and flexible film, containing naltrexone hydrochloride and other… More